(Q51644226)

8 April 2018

title

SEOM clinical guidelines for the treatment of advanced colorectal cancer. (English)

1 reference

8 April 2018

1 reference

Rocío García-Carbonero

1

1 reference

8 April 2018

author name string

M Auxiliadora Gómez España

2

1 reference

8 April 2018

Enrique Casado Sáenz

3

1 reference

8 April 2018

Vicente Alonso Orduña

4

1 reference

8 April 2018

Andrés Cervantes Ruipérez

5

1 reference

8 April 2018

Javier Gallego Plazas

6

1 reference

8 April 2018

Pilar García Alfonso

7

1 reference

8 April 2018

Ignacio Juez Martel

8

1 reference

8 April 2018

Encarnación González Flores

9

1 reference

8 April 2018

María Lomas Garrido

10

1 reference

8 April 2018

Dolores Isla Casado

11

1 reference

8 April 2018

SEOM (Spanish Society for Medical Oncology)

12

1 reference

8 April 2018

publication date

1 November 2010

1 reference

8 April 2018

Clinical and Translational Oncology

published in

1 reference

8 April 2018

volume

12

1 reference

8 April 2018

issue

11

1 reference

8 April 2018

page(s)

729-734

1 reference

8 April 2018

https://scigraph.springernature.com/pub.10.1007/s12094-010-0587-4

exact match

0 references

cites work

Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0587-4

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-010-0587-4

Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

21 January 2018

1 reference

12 December 2020

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

1 reference

12 December 2020

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Trends in long-term survival following liver resection for hepatic colorectal metastases

1 reference

12 December 2020

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

12 December 2020

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

12 December 2020

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

1 reference

12 December 2020

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

12 December 2020

Cetuximab for the treatment of colorectal cancer.

1 reference

12 December 2020

Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

12 December 2020

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

12 December 2020

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

12 December 2020

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

1 reference

12 December 2020

10.1007/S12094-010-0587-4

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018